SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs secures patent for 'Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation'

15 Feb 2025 Evaluate

Akums Drugs & Pharmaceuticals has secured a patent for its Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation, designed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The patent is valid for a term of 20 years.

In India, glaucoma affects approximately 11.9 million people, contributing to 12.8% of blindness cases. Among adults aged 40 years and above, the prevalence of glaucoma ranges from 2.7% to 4.3%. Addressing this critical ophthalmic challenge, Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation offers a key advantage over traditional eye drops containing preservatives like benzalkonium chloride, which can cause ocular surface irritation, dryness, and discomfort with prolonged use. By eliminating Benzalkonium Chloride, this innovative formulation enhances patient comfort, making it particularly beneficial for individuals those requiring long-term glaucoma management.

Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. 


Akums Drugs & Pharma Share Price

624.30 -1.90 (-0.30%)
06-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1913.05
Dr. Reddys Labs. 1368.75
Cipla 1471.25
Zydus Lifesciences 1148.05
Lupin 2492.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: